Cancer Stem Cell News Volume 3.05 | Feb 12 2014


    Cancer Stem Cell News 3.05 February 12, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

    Identification of Functional Cooperative Mutations of SETD2 in Human Acute Leukemia
    Investigators observed a global loss of H3K36 trimethylation in leukemic blasts with mutations in SETD2. In the presence of a genetic lesion, downregulation of SETD2 contributed to both initiation and progression during leukemia development by promoting the self-renewal potential of leukemia stem cells. [Nat Genet]
    Abstract | Press Release
    [Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.

    PUBLICATIONS (Ranked by impact factor of the journal)
    Tumor-Propagating Cells and Yap/Taz Activity Contribute to Lung Tumor Progression and Metastasis
    Scientists demonstrated that murine tumor propagating cells with the markers Sca1 and CD24 are enriched for metastatic potential in orthotopic transplantation assays. [EMBO J] Abstract

    shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer
    Scientists showed that MMTV-Her2/Neu mammary tumor cells cultured as non-adherent spheres or as adherent monolayer cells select for stabilizing mutations in p53 that “immortalize” the cultures, and that after serial passages, sphere conditions maintain tumor-initiating cells whereas monolayer cells gradually lose these tumorigenic cells. [Cancer Res] Abstract

    Activated Leukocyte Cell Adhesion Molecule (CD166); An ‘Inert’ Cancer Stem Cell Marker for Non-Small Cell Lung Cancer?
    CD166 was identified as an ‘inert’ cancer stem cell marker for non-small cell lung cancer (NSCLC). Researchers evaluated the expression of CD166 using immunohistochemistry in a large cohort of NSCLC patients on a tissue microarray basis. [Stem Cells] Abstract

    EMT and Acquisition of Stem Cell-Like Properties Are Involved in Spontaneous Formation of Tumorigenic Hybrids between Lung Cancer and Bone Marrow-Derived Mesenchymal Stem Cells
    Investigators found that spontaneously-formed tumorigenic hybrids between bone marrow-derived mesenchymal stem cells and three different non-small cell lung cancer cell lines contributed to highly malignant subpopulations with both epithelial-to-mesenchymal transition (EMT) and stem cell-like properties. [PLoS One] Full Article

    Response of Breast Cancer Cells and Cancer Stem Cells to Metformin and Hyperthermia Alone or Combined
    Metformin was preferentially cytotoxic to CD44high/CD24low cells of MCF-7 cells and, CD44high/CD24high cells of MIA PaCa-2 cells, which are known to be cancer stem cells of MCF-7 cells and MIA PaCa-2 cells, respectively. [PLoS One] Full Article

    Loss of WISP2/CCN5 in Estrogen-Dependent MCF7 Human Breast Cancer Cells Promotes a Stem-Like Cell Phenotype
    Researchers report that loss of Wnt-1-induced signaling protein-2 (WISP2) in MCF7 breast cancer cells can also promote the emergence of a cancer stem-like cell phenotype characterized by high expression of CD44, increased aldehyde dehydrogenase activity and mammosphere formation. [PLoS One] Full Article

    Attenuated Listeria monocytogenes as a Cancer Vaccine Vector for the Delivery of CD24, a Biomarker for Hepatic Cancer Stem Cells
    A new strategy involving genetic modification of the replication-deficient Listeria monocytogenes strain ΔdalΔdat (Lmdd) to express and secrete human CD24 protein has been developed. CD24 is a hepatic cancer stem cell biomarker that is closely associated with apoptosis, metastasis and recurrence of hepatocellular carcinoma. After intravenous administration in mice, Lmdd-CD24 was distributed primarily in the spleen and liver and did not cause severe organ injury. [Cell Mol Immunol] Abstract

    Expression of the Cancer Stem Cell Markers CD44v6 and ABCG2 in Tongue Cancer: Effect of Neoadjuvant Chemotherapy on Local Recurrence
    Scientists showed that a deep surgical margin was resected very close to the tumor site in many neoadjuvant chemotherapy (NAC)-treated oral squamous cell carcinoma patients, suggesting that NAC may lead to local recurrence and poor outcomes. [Int J Oncol] Abstract

    Win a $25 Amazon Gift Card!
    Connexon Creative is evaluating reader interest in a new social media platform. Fill out this quick survey for your chance to win 1 of 4 $25 gift cards! Take survey here

    Robust Growth of Human Mammary Luminal & Myoepithelial Cells with Serum-Free EpiCult-C (Human) Request a Free Sample

    MicroRNA Control of Epithelial-Mesenchymal Transition in Cancer Stem Cells
    This review summarizes the current understanding of the regulatory mechanisms of epithelial-mesenchymal transition (EMT) in cancer stem cells (CSC) initiation, with a special focus on the role of microRNAs in EMT control, and a discussion the implications of targeting CSCs for cancer therapeutics. [Int J Cancer] Abstract

    Discontinuation of Tyrosine Kinase Inhibitors and New Approaches to Target Leukemic Stem Cells: Treatment-Free Remission as a New Goal in Chronic Myeloid Leukemia
    The authors report the results of several published discontinuation studies and critically discuss the new approaches and tools to monitor residual disease during treatment and new strategies to target leukemic stem cells to reach a potential “operational” cure and persistent long-term leukemia-free survival. [Cancer Lett] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Cerulean Announces First Patient Dosed in Phase II Clinical Trial of CRLX101 in Combination with Avastin® in Relapsed Ovarian Cancer
    Cerulean Pharma Inc. announced that the first patient has been dosed in an open label single-arm Phase II clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. [Cerulean Pharma Inc.] Press Release

    City of Hope Researcher Receives Five Grants Totaling $450,000 to Fight Pediatric Brain Tumors
    Despite continual advances in the treatment of brain tumors, infants and children diagnosed with medulloblastoma – a fast-growing tumor in the cerebellum portion of the brain – still face significant challenges overcoming this disease. One particularly tricky obstacle is the blood-brain barrier, which prevents cancer drugs from passing into the brain and attacking the tumor. Margarita Gutova, M.D. may have found a way to bypass that hurdle – using neural stem cells. [Newswise, Inc.] Press Release | Video

    From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW American Society of Clinical Oncology (ASCO) 50th Annual Meeting
    May 30-June 3, 2014
    Chicago, United States

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Researcher – Molecular Biology and Cancer Research (Washington State University)

    Postdoctoral Position – Molecular Mechanisms of Cell Division (Memorial Sloan Kettering Cancer Center)

    Postdoctoral Position – Stem Cell Signaling and Epigenetics (Fondazione Istituto Nazionale Genetica Molecolare)

    Research Assistant – Stem Cell & Leukemia Epigenetic (King’s College London)

    Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

    Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

    Postdoctoral Position – Epigenetics and Cancer Biology (MPI Bad Nauheim)

    PhD Candidates – Stem Cells and Biomedical Engineering (Queensland University of Technology)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or Suggestions? Email Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us